ValueScreener

ValueScreener company report

GlucoTrack, Inc. (GCTK)

NASDAQ / Healthcare / Medical - Instruments & Supplies

Share price

0.83 USD Market dataClose of Oct 15, 2026

Market capitalisation

664.0K USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 30, 2026
Ratios computed
Oct 15, 2026
Filed years
22, FY2003 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-685.6% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

0.01x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

Read cash generation

Revenue and net income, as filed

FY2016 Revenue: 611.7K USDFY2016 Net income: -5.4M USDFY2017 Revenue: 589.5K USDFY2017 Net income: 10.3M USDFY2018 Revenue: 17.00B USDFY2018 Net income: -6.7M USDFY2019 Revenue: 208.0K USDFY2019 Net income: 3.5M USDFY2020 Net income: -2.7M USDFY2021 Net income: -4.1M USDFY2022 Net income: -4.4M USDFY2023 Net income: -7.1M USDFY2024 Net income: -22.6M USDFY2025 Net income: -19.4M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
1 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -685.6% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Medical - Instruments & Supplies industry (51 companies), -685.6% sits at the 0th percentile; the middle half of that group runs from -47.7% to 8.8%.

Is it safe

Current ratio was 1.61 in FY2025, in the band labelled "Adequate" (1.50 to 2.00), on lines anchored on Graham's defensive-investor criteria.

Today, against the Medical - Instruments & Supplies industry (50 companies), 1.61 sits at the 15th percentile; the middle half of that group runs from 1.79 to 4.39.

Year by year against peers
Whether GlucoTrack, Inc.'s current ratio stayed above the median of the Medical - Instruments & Supplies industry, year by year. (FY2023 to FY2025, 3 fiscal years of GlucoTrack, Inc. with a comparable figure)
The direction
Which way GlucoTrack, Inc.'s current ratio has moved, and how steadily. (FY2016 to FY2025, 10 filed years of GlucoTrack, Inc.)
What could explain it
What in GlucoTrack, Inc.'s filed statements could explain the movements. (4 readings drawn from the statement lines GlucoTrack, Inc. filed)
What to check next
What to check next on GlucoTrack, Inc., and where in its filings. (3 questions for GlucoTrack, Inc.)
In one paragraph
One paragraph on GlucoTrack, Inc.'s returns, cash, balance sheet and price. (4 of sixteen figures read for GlucoTrack, Inc.)

These are GCTK’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research GCTKPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 30, 2026, accession 0001493152-26-013656.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

GlucoTrack, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Return on equity-685.6% ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Return on capital employed, pre-tax-525.0% ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Return on assets-247.4% ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Gross margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Operating margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Net margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

GlucoTrack, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Current ratio1.61 ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Quick ratio1.61 ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Altman Z-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Total assets 7.8MTotal liabilities 5.0MShareholders' equity 2.8MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What GlucoTrack, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 30, 2026, 0001493152-26-013656).

GlucoTrack, Inc: balance sheet position
Total assets7.8M FiledFY2025 10-K, filed Mar 30, 2026
Total liabilities5.0M FiledFY2025 10-K, filed Mar 30, 2026
Shareholders' equity2.8M FiledFY2025 10-K, filed Mar 30, 2026
Cash7.4M FiledFY2025 10-K, filed Mar 30, 2026
Total debtn/a FiledFY2025 10-K, filed Mar 30, 2026
Net debtn/a
Current ratio1.61
Debt to equityn/a
  • Debt to equity: FY2025: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2025: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

GlucoTrack, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
P/E on trailing twelve months0.02x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book0.01x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Price to sales
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Price to earnings over growth
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Diluted earnings per share468.30 USD FiledFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Graham number
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656

We publish no fair value or price target of our own. Value GCTK on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for GlucoTrack, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

GlucoTrack, Inc: valuation
Share price0.83 USD
Market capitalisation664.0K USD
Enterprise value to EBITDAn/m
Graham numbern/a
Diluted earnings per share, FY2025468.30 USD

Diluted earnings per share, FY2025: 31.22 as filed, 468.30 after the 1-for-15 split on 31 Aug 2026.

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Oct 3, 2016: low 0.00x, median 18.96x, high 1733.33x, latest 0.02x. 1,380 trading days with a meaningful ratio, 1,142 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like GlucoTrack, Inc

  1. WORK Medical Technology Group Ltd. (WOK)Market cap 3.2M USD
  2. NEXGEL, Inc. (NXGL)Market cap 109.8K USD
  3. Jin Medical International Ltd. (ZJYL)Market cap 16.9M USD
  4. Milestone Scientific Inc. (MLSS)Market cap 29.6M USD
  5. Femasys Inc. (FEMY)Market cap 14.5M USD

Same industry (Medical - Instruments & Supplies) and size band (Nano, under 50M), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

GlucoTrack, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Free cash flow-15.3M USD ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Free cash flow margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
FY2016 Free cash flow: -5.4M USDFY2016 Net income: -5.4M USDFY2017 Free cash flow: -5.9M USDFY2017 Net income: 10.3M USDFY2018 Free cash flow: -4.9M USDFY2018 Net income: -6.7M USDFY2019 Free cash flow: -3.9M USDFY2019 Net income: 3.5M USDFY2020 Free cash flow: -3.6M USDFY2020 Net income: -2.7M USDFY2021 Free cash flow: -3.8M USDFY2021 Net income: -4.1M USDFY2022 Free cash flow: -3.7M USDFY2022 Net income: -4.4M USDFY2023 Net income: -7.1M USDFY2024 Free cash flow: -12.6M USDFY2024 Net income: -22.6M USDFY2025 Free cash flow: -15.3M USDFY2025 Net income: -19.4M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

GlucoTrack, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/aFY2025Oct 15, 2026
n/a The filed earnings per share contradicts the net income on the same statement, so we will not divide a price by it.
0.01xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Mar 30, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/aFY2025Mar 30, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
1.61FY2025Mar 30, 2026
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Oct 15, 2026
n/a This figure compares a year against the one before it, and we hold one filed year for this company.
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 30, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 30, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 22 filed fiscal years on record, FY2003 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports GlucoTrack, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

GlucoTrack, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025n/a-16.1M-19.4M468.30-15.3Mn/a-685.6%10-K, Mar 30, 20260001493152-26-013656
FY2024n/a-14.5M-22.6M61590.00-12.6Mn/an/m10-K, Mar 31, 20250001641172-25-001861
FY2023n/a-7.1M-7.1M30762.00n/an/a-222.0%10-K, Mar 28, 20240001493152-24-011765
FY2022n/a-4.4M-4.4M1305.00-3.7Mn/a-360.6%10-K, Mar 31, 20230001493152-23-010356
FY2021n/a-4.0M-4.1M1170.00-3.8Mn/a-78.9%10-K, Mar 31, 20220001493152-22-008417
FY2020n/a-3.1M-2.7M855.00-3.6Mn/a-30.0%10-K, Apr 13, 20210001493152-21-008654
FY2019208.0K3.5M3.5M-1170.00-3.9Mn/an/m10-K, Apr 14, 20200001493152-20-006370
FY201817.00B-6.5M-6.7M-277290.00-4.9M-0.0%n/m10-K, Apr 15, 20190001493152-19-005323
FY2017589.5K10.6M10.3M-109395.00-5.9Mn/an/m10-K, Mar 30, 20180001178913-18-001056
FY2016611.7K-5.7M-5.4M-63180.00-5.4M-924.6%n/m10-K, Mar 31, 20170001178913-17-001006
  • Revenue, compound annual growth FY2016 to FY2019: -30.2%
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

GlucoTrack, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Piotroski F-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 30, 2026, 0001493152-26-013656
Named tests met1 of 30 Computed
Beta2.33 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 1 met, 11 not met, 18 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
Cheapest quarter on P/B (David Dreman)
Does not
Defensive investor (Benjamin Graham); Large cap, low P/E; High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Cash-flow yield and ROIC
Not measured
Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; ROIC at or above WACC; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(22)
  • Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Piotroski F-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • P/E Ratio: We do not hold this figure for this company, so there is nothing to show.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Beneish M-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • PEG Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Gross Margin: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Asset Turnover: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Ncav: The filed share count no longer matches today's share, after a split or new shares since the fiscal year, so the two do not compare.
  • Price To Graham: We do not hold this figure for this company, so there is nothing to show.
  • P/S Ratio: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 22 figures could not be read on this company, among them Debt to Equity, Piotroski F-Score, P/E Ratio. Each blank in the table above names the rest, with its reason. 18 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy